Key Development Details
Concord Biotech Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Product Description and Indication
Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants. It is used in combination with other immunosuppressants.
Market Opportunity
According to market estimates provided in the disclosure, the U.S. market for Mycophenolate Mofetil is approximately US$ 30 million.
Strategic Rationale and Impact
The approval is stated to be in line with Concord Biotech's growth strategy. It is expected to:
- Position the Company to capitalize on attractive market opportunities
- Enhance the Company's product offerings
- Support its long-term growth strategy across the U.S. and international markets
- Strengthen the Company's position in the U.S. market
Financial Impact
No specific quantified financial impact, monetary value of the approval, or projected revenue from the product is disclosed in the filing.
Effective Date and Validity
The disclosure does not specify the effective date of the approval or the period for which the approval is valid.
Company Representative
The disclosure was signed by Paritosh Trivedi, Company Secretary & Compliance Officer (ACS 63623).
#Tags: #ConcordBiotech #USFDA #ANDAApproval #SEBIDisclosure #RegulatoryCompliance #Pharmaceuticals #Neutral